Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245834 | 0.95 | NPC1 (0.43) | ITGB3ITGA2BCHRM4NPC1RAB9A | |
| SCHEMBL4244678 | 0.95 | NPC1 (0.40) | ITGB3ITGA2BCHRM4NPC1RAB9A | |
| SCHEMBL4245882 | 0.94 | NPC1 (0.42) | CHRM4NPC1RAB9AL3MBTL1MAPK14 | |
| SCHEMBL4249956 | 0.88 | TDP1 (0.44) | CYP2C9MAPK14MAPK11 | |
| SCHEMBL4245881 | 0.86 | TDP1 (0.51) | NPC1L3MBTL1 | |
| SCHEMBL4249017 | 0.86 | TDP1 (0.48) | NPC1L3MBTL1 | |
| SCHEMBL4244301 | 0.85 | TDP1 (0.53) | L3MBTL1 | |
| SCHEMBL4252805 | 0.85 | ROCK2 (0.42) | ITGB3ITGA2BCHRM4MAPK14 | |
| SCHEMBL4247544 | 0.83 | TDP1 (0.49) | NPC1L3MBTL1 | |
| SCHEMBL4252787 | 0.83 | TDP1 (0.51) | NPC1RAB9ACYP2C9MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902400-B2 | N-(1,1-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; N-(2,2-diemthylpropyl)-4-(2-propynyloxy)-3-methoxybenzamide; controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20090131531-A1 | Amide Compounds and their Use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1940780-A1 | AMIDE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007049728-A1 | AMIDE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131531-A1 | Amide Compounds and their Use | NAT1, ACAT2, NAAA | ITGB3 4855/4885ITGA2B 4742/4885CHRM4 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.